Overview

Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children.

Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
Efficacy/Safety of T1225, in comparison to reference product, for the treatment of purulent bacterial conjunctivitis of children.
Phase:
Phase 3
Details
Lead Sponsor:
Laboratoires Thea
Treatments:
Tobramycin